| Literature DB >> 26561800 |
Francisco Javier Rodriguez-Jimenez1, Ana Alastrue-Agudo2, Miodrag Stojkovic3,4, Slaven Erceg5, Victoria Moreno-Manzano6.
Abstract
Ion channels included in the family of Connexins (Cx) help to control cell proliferation and differentiation of neuronal progenitors. Here we explored the role of Connexin 50 (Cx50) in cell fate modulation of adult spinal cord derived neural precursors located in the ependymal canal (epSPC). epSPC from non-injured animals showed high expression levels of Cx50 compared to epSPC from animals with spinal cord injury (SCI) (epSPCi). When epSPC or epSPCi were induced to spontaneously differentiate in vitro we found that Cx50 favors glial cell fate, since higher expression levels, endogenous or by over-expression of Cx50, augmented the expression of the astrocyte marker GFAP and impaired the neuronal marker Tuj1. Cx50 was found in both the cytoplasm and nucleus of glial cells, astrocytes and oligodendrocyte-derived cells. Similar expression patterns were found in primary cultures of mature astrocytes. In addition, opposite expression profile for nuclear Cx50 was observed when epSPC and activated epSPCi were conducted to differentiate into mature oligodendrocytes, suggesting a different role for this ion channel in spinal cord beyond cell-to-cell communication. In vivo detection of Cx50 by immunohistochemistry showed a defined location in gray matter in non-injured tissues and at the epicenter of the injury after SCI. epSPCi transplantation, which accelerates locomotion regeneration by a neuroprotective effect after acute SCI is associated with a lower signal of Cx50 within the injured area, suggesting a minor or detrimental contribution of this ion channel in spinal cord regeneration by activated epSPCi.Entities:
Keywords: connexins; ependymal stem progenitor cells; spinal cord
Mesh:
Substances:
Year: 2015 PMID: 26561800 PMCID: PMC4661840 DOI: 10.3390/ijms161125981
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1Cx50 expression in epSPC compared to epSPCi and their derived differentiated cells. (A) Cx50 exhibited higher protein expression in epSPC compared to activated epSPCi; (B) Immunocytochemical analysis of Cx50 simultaneously with the markers for the neuronal lineage (GFAP for astrocytes, Olig1 for oligodendrocytes and Tuj1 for neurons) in epSPC and epSPCi under spontaneous differentiation conditions for 24 h. The inset shows a zoom in area for easier visualization of Olig1 and Cx50 co-localization. Arrows point double-stainings. Scale bar = 100 µm; (C) Quantification of co-localization for Cx50 and Olig1; *** p < 0.001 vs. epSPC; (D) Immunocytochemistry of Cx50 and GFAP antibodies in primary culture of mature astrocytes isolated from non-injured spinal cord rats. Scale bar = 100 µm; (E) Modulation of GFAP and Tuj1 in epSPCi after over-expression of Cx50 by using pCMV6-Cx50 expression vector in comparison to pCMV6-empty (control).
Figure 2Evolution of Cx50 mRNA expression of epSPC and epSPCi during directed differentiation to oligodendrocytes. (A) Changes in Cx50 mRNA expression determined by qRT-PCR during directed differentiation to oligodendrocytes; (B) Changes in total Cx50 protein expression of epSPC and epSPCi during directed differentiation to oligodendrocytes; (C) Subcellular fractionation of proteins from epSPC and epSPCi shows evolution of nuclear expression of Cx50, Oct4 and Sox2 during directed differentiation to oligodendrocytes. PCNA was used as differentiation control; (D) Immunostaining of Cx50 and mature oligodendrocyte marker RIP in epSPCi after 21 days of differentiation. Scale bar = 100 µm (upper panel); 10 µm (lower panel).
Figure 3Cx50 expression in healthy spinal cord tissue, after SCI, and epSPCi transplantation. Immunohistochemical evaluation of Cx50 and the astrocytic marker GFAP in tissues from (A) non-injured spinal cord and 2 months after SCI (Zoom; Cx50/GFAP/DAPI); Scale bar = 25 µm, and (B) 2 months after SCI with GFP-epSPCi transplantation (Zoom; epSPCi/TuJ1/Cx50); * epicenter of the injury area.